134 related articles for article (PubMed ID: 36550801)
1. Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy.
Loosen SH; Kostev K; Eschrich J; Krieg S; Krieg A; Luedde T; Jann H; Roderburg C
Medicine (Baltimore); 2022 Dec; 101(50):e32044. PubMed ID: 36550801
[TBL] [Abstract][Full Text] [Related]
2. Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study.
Loosen SH; Kostev K; Jann H; Tetzlaff F; Tacke F; Krieg S; Knoefel WT; Fluegen G; Luedde T; Krieg A; Roderburg C
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1411-1416. PubMed ID: 35476234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
[TBL] [Abstract][Full Text] [Related]
4. Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe.
Jann H; Krieg S; Krieg A; Eschrich J; Luedde T; Kostev K; Loosen S; Roderburg C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7557-7563. PubMed ID: 36971798
[TBL] [Abstract][Full Text] [Related]
5. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
6. Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: A 20-year single-center retrospective analysis.
You T; Tang H; Xu X; Ying H; Sun Z; Cheng Y; Bai C
J Neuroendocrinol; 2022 Dec; 34(12):e13211. PubMed ID: 36373196
[TBL] [Abstract][Full Text] [Related]
7. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
[TBL] [Abstract][Full Text] [Related]
9. Cystic Pancreatic Neuroendocrine Tumors Represent a Distinct Clinical Entity with Less Aggressive Biological Behaviors.
Cheng Y; Wu D; Wang L; Liu H; Xiong Y; Xu J; Hu S; Zhan H
J Surg Res; 2021 Apr; 260():134-140. PubMed ID: 33340866
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
11. Sex-Based Clinicopathologic and Survival Differences Among Patients with Pancreatic Neuroendocrine Tumors.
Greenberg JA; Ivanov NA; Egan CE; Lee YJ; Zarnegar R; Fahey TJ; Finnerty BM; Min IM
J Gastrointest Surg; 2022 Nov; 26(11):2321-2329. PubMed ID: 35915373
[TBL] [Abstract][Full Text] [Related]
12. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
13. [PANCREATIC NEUROENDOCRINE TUMORS (PNET): THE DILEMMA OF SURGERY VS. WATCHFUL WAITING APPROACH].
Shafir M; Harel R; Sandler V; Haddad R; Khoury W; Bitterman A
Harefuah; 2022 Nov; 161(11):687-694. PubMed ID: 36578240
[TBL] [Abstract][Full Text] [Related]
14. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
Kim D; Viswanathan K; Goyal A; Rao R
Cancer Cytopathol; 2020 Apr; 128(4):269-277. PubMed ID: 31977134
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
16. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group.
Klein Haneveld MJ; van Treijen MJC; Pieterman CRC; Dekkers OM; van de Ven A; de Herder WW; Zandee WT; Drent ML; Bisschop PH; Havekes B; Vriens MR; Verrijn Stuart AA; Valk GD; van Leeuwaarde RS
J Clin Endocrinol Metab; 2021 Nov; 106(12):3515-3525. PubMed ID: 34333645
[TBL] [Abstract][Full Text] [Related]
17. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.
Gurung B; Hua X; Runske M; Bennett B; LiVolsi V; Roses R; Fraker DA; Metz DC
Cancer Biol Ther; 2015; 16(2):219-24. PubMed ID: 25482929
[TBL] [Abstract][Full Text] [Related]
18. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
20. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
